Afficher la couverture 'Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer | Guérin, Mathilde' en grand format
/5

0 avis

Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer

Archive ouverte

Guérin, Mathilde | Gonçalves, Anthony | Toiron, Yves | Baudelet, Emilie | Pophillat, Matthieu | Granjeaud, Samuel | Fourquet, Patrick | Jacot, William | Tarpin, Carole | Sabatier, Renaud | Agavnian, Emilie | Finetti, Pascal | Adelaïde, José | Birnbaum, Daniel | Ginestier, Christophe | Charafe-Jauffret, Emmanuelle | Viens, Patrice | Bertucci, François | Borg, Jean-Paul | Camoin, Luc

Edité par CCSD ; Impact journals -

International audience. treatments targeting the Human Epidermal Growth Factor Receptor 2 (HER2/ERBB2) have improved the natural history of HER2-positive breast cancer. However, except HER2 protein expression and gene amplification, there is no predictive biomarker to guide the HER2-targeted therapies. We developed Parallel reaction monitoring (PRM) a powerful approach, to quantify and evaluate key proteins involved in the HER2 pathway and/or anti-HER2 treatment sensitivity.

Suggestions

Du même auteur

Poly(ADP-Ribose) Polymerase 1 (PARP1) Overexpression in Human Breast Cancer Stem Cells and Resistance to Olaparib

Archive ouverte | Gilabert, Marine | CCSD

International audience. Background: Breast cancer stem cells (BCSCs) have been recognized as playing a major role in various aspects of breast cancer biology. To identify specific biomarkers of BCSCs, we have perfor...

Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study

Archive ouverte | Gonçalves, Anthony | CCSD

International audience. Background: Routine feasibility and clinical impact of genomics-based tumor profiling in advanced breast cancer (aBC) remains to be determined. We conducted a pilot study to evaluate whether ...

ZNF703 gene amplification at 8p12 specifies luminal B breast cancer

Archive ouverte | Sircoulomb, Fabrice | CCSD

International audience. Luminal B breast cancers represent a fraction of oestrogen receptor (ER)-positive tumours associated with poor recurrence-free and disease-specific survival in all adjuvant systemic treatment...

Chargement des enrichissements...